Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.59 |
| ▸ | TACR2 | P21452 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SHBG | P04278 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | TST | Q16762 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1451841 | 1.00 | ESR1 (0.59) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL30712275 | 1.00 | ESR1 (0.59) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL10354229 | 1.00 | ESR1 (0.59) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL23037542 | 1.00 | ESR1 (0.59) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL29013341 | 1.00 | ESR1 (0.59) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL23302919 | 1.00 | ESR1 (0.59) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| Hydrochloric Acid SCHEMBL23303513 | 0.98 | ESR1 (0.57) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL20633866 | 0.98 | CHKA (0.56) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| SCHEMBL727512 | 0.91 | ALDH1A1 (0.56) | ESR1ADRA2AADORA3TACR2SLC6A2 | |
| Hydrochloric Acid SCHEMBL2868873 | 0.89 | ALDH1A1 (0.54) | ESR1ADRA2AADORA3TACR2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250107971-A1 | POWDER-LIQUID-TYPE DENTAL PLATE LINER | TOKUYAMA DENTAL CORPORATION (JP) | 2025-04-03 | — | — | US | disclosed |
| EP-4464302-A1 | POWDER-LIQUID-TYPE DENTURE BASE LINER | Tokuyama Dental Corporation (JP) | 2024-11-20 | — | — | EP | disclosed |
| US-20240018279-A1 | Cyclic Containing Polymer Compositions Obtained Using Transition Metal Bis(Phenolate) Catalyst Complexes and Process for Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230357454-A1 | Methods for Delivery of Non-Aromatic Solutions to Polymerization Reactors | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230348640-A1 | Propylene Copolymers Obtained Using Transition Metal Bis(Phenolate) Catalyst Complexes and Homogeneous Process for Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348642-A1 | Ethylene-Alpha-Olefin-Diene Monomer Copolymers Obtained Using Transition Metal Bis(Phenolate) Catalyst Complexes and Homogeneous Process for Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348634-A1 | Propylene Polymers Obtained Using Transition Metal Bis(Phenolate) Catalyst Complexes and Homogeneous Process for Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230312772-A1 | Multidentate Lewis Base Catalysts and Methods for use Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-10-05 | — | — | US | disclosed |
| US-11766669-B2 | Hexahydrocyclopenta[e]-as-indacen-1-yl and octahydrobenzo[e]-as-indacen-1-yl based catalyst complexes and process for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230287156-A1 | Polyethylene Compositions Obtained Using Transition Metal Bis(Phenolate) Catalyst Complexes and Homogeneous Process for Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-09-14 | — | — | US | disclosed |
| WO-2023135930-A1 | POWDER-LIQUID-TYPE DENTURE BASE LINER | 株式会社トクヤマデンタル | 2023-07-20 | — | — | WO | disclosed |
| US-20230212330-A1 | Metallocene Catalysts for Producing Vinyl-Terminated Polyalphaolefins and Methods Associated Therewith | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-11661465-B2 | Dimer selective metallocene catalysts, non-aromatic hydrocarbon soluble activators, and processes to produce poly alpha-olefin oligmers therewith | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230141606-A1 | Alkylation of Transition Metal Coordination Catalyst Complexes | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11414436-B2 | Non-coordinating anion type activators containing cation having large alkyl groups | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| EP-1219625-B1 | Novel substituted 2-(6-benzyl-5-oxo-3-phenyl-(S3,7S,7AR)- perhydroimidazol (1,5-C) (1,3) thiazol-7YL) compounds | COUNCIL SCIENT IND RES (IN) | 2006-05-17 | — | — | EP | disclosed |
| US-6486328-B1 | Substituted 2-[-6-benzyl-5-oxo-3-phenyl-(3s,7s, 7aR)-perhydroimidazol[1,5-c][1,3]thiazol-7yl] compounds | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2002-11-26 | — | — | US | disclosed |
| EP-1219625-A1 | Novel substituted 2-(6-benzyl-5-oxo-3-phenyl-(S3,7S,7AR)- pherhydroimidazol (1,5-C) (1,3) thiazol-7YL) compounds | Council of Scientific and Industrial Research (IN) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141606-A1 | Alkylation of Transition Metal Coordination Catalyst Complexes | AS3MT, AP1M1, AP3M1 | ESR1 3347/4885ADRA2A 3882/4885ADORA3 2987/4885 |
| US-20250107971-A1 | POWDER-LIQUID-TYPE DENTAL PLATE LINER | HEATR1, HEATR6, ACTR5 | ESR1 2998/4885ADRA2A 3288/4885ADORA3 3058/4885 |
| US-11414436-B2 | Non-coordinating anion type activators containing cation having large alkyl groups | KCNK10, KCNK4, HCN4 | ESR1 986/4885ADRA2A 1018/4885ADORA3 665/4885 |
| US-11766669-B2 | Hexahydrocyclopenta[e]-as-indacen-1-yl and octahydrobenzo[e]-as-indacen-1-yl based catalyst complexes and process for use thereof | MLX, ZYX, TXN | ESR1 569/4885ADRA2A 2659/4885ADORA3 2526/4885 |
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | SDCBP, DDOST, KRTCAP2 | ESR1 3513/4885ADRA2A 2992/4885ADORA3 4752/4885 |
| US-11661465-B2 | Dimer selective metallocene catalysts, non-aromatic hydrocarbon soluble activators, and processes to produce poly alpha-olefin oligmers therewith | NONO, TPR, ZNF787 | ESR1 1036/4885ADRA2A 1022/4885ADORA3 1956/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | ESR1 1538/4885ADRA2A 2814/4885ADORA3 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.